Current Limitations of IBD Treatment
Where Do We Go from Here?
Article first published online: 24 AUG 2006
Annals of the New York Academy of Sciences
How to Cite
TARGAN, S. R. (2006), Current Limitations of IBD Treatment. Annals of the New York Academy of Sciences, 1072: 1–8. doi: 10.1196/annals.1326.032
- Issue published online: 24 AUG 2006
- Article first published online: 24 AUG 2006
- inflammatory bowel disease;
- biologic therapy;
- anti-tumor necrosis factor (TNF);
- mucosal inflammation
Abstract: Great progress has been made over the last decade in the development of targeted specific therapies for inflammatory bowel disease. Nevertheless, accumulating experience with these modalities and results from ongoing investigations of agents currently on the market and those in development have demonstrated that efficacy may be limited to certain patient phenotypes. Recently, great interest has been applied to studies of the interplay between the adaptive and innate immune responses to achieve a better understanding of the immunopathogeneses of inflammatory bowel diseases as well as to identify targets for even more potent intervention.